CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用 LIGHT 增强 CAR-T 细胞功能
英文原题：Augmenting CAR T-cell Functions with LIGHT.
查看英文原题
Augmenting CAR T-cell Functions with LIGHT.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 治疗血液恶性肿瘤临床成功显著，但实体瘤疗效受靶抗原异质性限制。为克服这一问题，研究者构建过表达LIGHT的CAR-T 细胞。LIGHT可结合癌细胞上的淋巴毒素β受体及免疫细胞上的疱疹病毒进入介质受体。此类细胞既能通过CAR依赖机制识别抗原，也能通过LIGHT与癌细胞受体相互作用产生抗原非依赖性杀伤；同时具有免疫刺激作用，可改善细胞增殖和细胞毒特征。结果提示LIGHT表达型CAR-T 可能清除抗原阴性肿瘤细胞，降低抗原阴性复发风险。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has resulted in remarkable clinical success in the treatment of B-cell malignancies.
However, its clinical efficacy in solid tumors is limited, primarily by target antigen heterogeneity. To overcome antigen heterogeneity, we developed CAR T cells that overexpress LIGHT, a ligand of both lymphotoxin- receptor on cancer cells and herpes virus entry mediator on immune cells. LIGHT-expressing CAR T cells displayed both antigen-directed cytotoxicity mediated by the CAR and antigen-independent killing mediated through the interaction of LIGHT with lymphotoxin- receptor on cancer cells.
Moreover, CAR T cells expressing LIGHT had immunostimulatory properties that improved the cells' proliferation and cytolytic profile. These data indicate that LIGHT-expressing CAR T cells may provide a way to eliminate antigen-negative tumor cells to prevent antigen-negative disease relapse.
论文信息
- 作者
- Cai W、Tanaka K、Mi X、Rajasekhar VK、Khan JF、Yoo S、de Stanchina E、Rahman J
- 第一作者单位
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.United States
- 通讯作者单位
- Memorial Sloan Kettering Cancer Center, New York, New York.United States
- 文献类型
- 美国 NIH 资助研究
- 期刊
- Cancer immunology research2024 Oct 1
- 原文标识
- PubMed 38959337 · DOI 10.1158/2326-6066.CIR-24-0246
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →